Results for
"[search-keyword]"
Sponsor content
339 result(s) found, displaying 51 to 60
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for WELIREG belzutifan 40 mg film-coated tablet bottle.
-
Australian Public Assessment Report (AusPAR)AusPAR for Keytruda (pembrolizumab) for the treatment of Oesophageal Cancer
-
Australian Public Assessment Report (AusPAR)AusPAR for Keytruda (pembrolizumab) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in-situ (CIS) with or without papillary tumours who are ineligible for or have elected not to undergo cystectomy.
-
Australian Public Assessment Report (AusPAR)AusPAR for Keytruda (pembrolizumab) for the treatment relapsed or refractory classical Hodgkin Lymphoma
-
Cancellation by sponsorRequested by Merck Sharp & Dohme (Australia) Pty Ltd
-
Prescription medicine registrationActive ingredients: HPV Type 11 L1 Protein, HPV Type 16 L1 Protein, HPV Type 18 L1 Protein, HPV Type 31 L1 Protein, HPV Type 33 L1 Protein, HPV Type 45 L1 Protein, HPV Type 52 L1 Protein, HPV Type 58 L1 Protein, HPV Type 6 L1 Protein.
-
Designation or determinationOrphan drug
-
Prescription medicine registrationActive ingredients: Pneumococcal purified capsular polysaccharides.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LAGEVRIO molnupiravir 200 mg capsules bottle.